New data extend understanding of Latuda's efficacy and safety
New data extend the understanding of the efficacy and safety of Latuda (lurasidone) in the treatment of schizophrenia.
These data, being presented today at the 23rd European Congress of Psychiatry (EPA) in Vienna, Austria, suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment.
The European subsidiary of Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) and partner USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese pharma major Dainippon Sumitomo’s (TYO: 4506), today announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda. Latuda was granted Marketing Authorization in the European Union for the treatment of schizophrenia in adults last year (The Pharma Letter March 28, 2014) and was cleared in the USA in 2010.
Key findings from the three abstracts include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze